Blog

Oral Wegovy Explained: OASIS-4 Results, Side Effects, Dosing and How Calocurb Fits In

Oral Wegovy Explained: OASIS-4 Results, Side Effects, Dosing and How Calocurb Fits In

OASIS-4

Thanks to the results of the OASIS-4 trial, oral semaglutide for weight loss was approved by the FDA in late December 2025 and hit the US market in early January. Sold as the “Wegovy pill”, the new formulation of a glycogen-like peptide-1 receptor agonist (GLP-1 RA) had already achieved sales of >18,000 prescriptions a week after its launch.1 The OASIS-4 trial demonstrated was a double-blind, placebo controlled trial in non-diabetic people with BMIs≥30 kg/m2 or ≥27 kg/m2 + at least one obesity-related complication.2 In total, 205 participants received oral semaglutide 25 mg once daily (with a 12-week dose escalation) versus 102 who received placebo; both groups also had lifestyle interventions. There were two primary endpoints: the percentage of participants who achieved ≥5% weight loss (i.e., clinically meaningful) and the percent change in body weight.

Bar chart comparing percentage of participants achieving ≥5%, ≥10%, ≥15%, and ≥20% weight loss with Semaglutide 25 mg vs placebo in the OASIS-4 trial

Efficacy

At 64 weeks, the semaglutide group lost an average of 13.6% compared to a 2.2% loss in the placebo group (p<0.001).2 This percentage point difference was comparable to that seen in the STEP-1 trial of subcutaneous semaglutide versus placebo and to the OASIS 1 trial of oral semaglutide 50 mg daily.3,4 The semaglutide group was significantly more likely to achieve weight losses of ≥5%, ≥10%, ≥15%, and ≥20% (p<0.001) as shown in Figure 1.

Figure 1: OASIS-4 Categorical Body Weight Reductions5

Side Effects

Adverse events were typical for GLP-1 receptor agonists. Gastrointestinal (GI) adverse events occurred in 74.0% of semaglutide subjects and 42.2% of placebo patients and were reported as mostly mild to moderate and transient.2 In all, nausea was experienced by 46.6% of the semaglutide group versus 18.6% for placebo, and vomiting occurred in 30.9% versus 5.9% (for semaglutide and placebo, respectively). Nevertheless, they led to study discontinuation in only 6.9% of the treatment group and 5.9% of the placebo group.2 Serious adverse events were seen in 3.9% of the treatment group and and 8.8% of the placebo group.2

Dosing

GLP-1 RAs are typically large molecules that are sensitive to gastric acids with little intestinal absorption. This version is formulated with 300 mg of salcaprozate sodium (SNAC), which temporarily raises the pH around the tablet within the stomach and also briefly increases the permeation of this macromolecule across the gastric epithelium.6 This allows gastric absorption of the semaglutide, though its true bioavailability is still much less than that of a subcutaneous injection, hence the need for a daily dose of 25 mg to achieve a similar effect to 2.4 mg subcutaneously once weekly.

Because of its SNAC formulation, oral semaglutide must not be chewed or cut in half.7 Patients are directed to take it first thing in the morning on waking, with only a little water (4 oz), and must not have any other food or drink (including coffee) for at least 30 minutes after ingestion. 7 As with other GLP-1 RAs, the dose must be slowly titrated up, typically every 30 days from 1.5 mg to 4 mg to 9 mg and finally 25 mg daily. 7 Consequently, most patients require at least 90 days of medication before they reach the effective dose of 25 mg daily.

The exception to titrating the dose is for patients moving from injectable semaglutide to the oral form, who can start at the highest dose.

Pricing

NovoNordisk has a direct-to-consumer channel with prices of $149/month for the 1.5 mg and 4 mg doses, and $299/month for the 9 mg and 25 mg doses. Amazon Pharmacy is also offering it, with same-day delivery, and it will be available on TrumpRx when that platform launches shortly.8

Oral Semaglutide and Calocurb

Calocurb® is an oral nutraceutical containing Amarasate®, a bitter extract of hop flowers grown in New Zealand that triggers bitter taste receptors on enteroendocrine L-cells throughout the gut, causing them to release GLP-1, cholecystokinin and peptide YY. These hormones activate central satiety pathways within the hypothalamus centrally and slow stomach emptying—signals to stop eating. Endogenous GLP-1, CCK and PYY typically rise we start to eat; when Calocurb was taken an hour before a meal, it doubled that natural peak (6.4 x baseline) and subjects subsequently ate 18% few calories.9 Calocurb can also be used to curb hunger during fasting (e.g., time-restricted eating). In 24h water-only fasts, it reduced overall hunger by 20% in men and by 30% in women; overall cravings decreased by 40% in women, who consequently ate >14% fewer calories.10,11

Similarities and Differences

Both oral agents must be swallowed whole on an empty stomach. Semaglutide requires a completely empty stomach for at least 30 minutes afterwards, to ensure the SNAC technology is not disrupted, rendering the dose ineffective. Users should not have even a cup of coffee. Calocurb users should not eat for at least an hour afterwards, to ensure it’s flushed through the stomach to allow the capsule to release the Amarasate in the upper small intestine. If transit is delayed through the stomach (e.g., by food), the Amarasate may be released there, where it’s more likely to cause nausea. However, having a cup of coffee (even with milk) is not likely to either reduce its effectiveness or increase nausea.

GI adverse events occur at a much higher rate with semaglutide, which activates GLP-1 receptors at supraphysiological levels. With Calocurb, around 5-10% of users experience transient diarrhea when they start it, due to the colonic flushing effect of the GLP-1 and CCK. This typically occurs with only the first few doses and only very seldom persists.

Both products must be titrated up, but it’s a much faster process with Calocurb. The nutraceutical takes around 5 days to reach the most commonly effective dose (250 mg taken before two meals a day for the standard portion reduction regimen); this is recommended to allow those who are more sensitive to the Amarasate to acclimate to the increasing levels of endogenous GLP-1 and CCK. In contrast, oral semaglutide takes 90 days to reach its most effective dose and for many patients, the GI effects persist throughout treatment.

Complementary Products?

Calocurb has been used concurrently with injectable GLP-1 RAs to allow reduction of the medication (and adverse events) while maintaining efficacy. It’s also likely to counter the blunting effect that the GLP-1 RAs have on the normal eating-induced rise in endogenous GLP-1.12 Given that the oral dose of semaglutide needed to achieve equivalent weight loss to the injections resulted in a high incidence of GI adverse effects, it makes sense that Calocurb could be used in a similar way with the pill form. This would work more practically for patients who do not take Calocurb first thing in the morning (e.g., to decrease hunger for the first few hours of time-restricted eating, or to reduce breakfast calories), as it would allow ingestion of the semaglutide on waking and the first dose of Calocurb later in the day.

Patients who stop taking oral semaglutide can use Calocurb as an exit strategy from the medication, allowing them to “kick start” their blunted endogenous GLP-1 production and to continue to support their weight management long-term. In such cases, they should be advised to start Calocurb ten days before they stop the medication.

Conclusion

The availability of the pill formulation of semaglutide means that those patients who are needle-phobic or even moderately uncomfortable with injecting themselves can now access the medication orally. The fast rise in sales seen since its launch perhaps reflect just how many patients fit into these categories. However, as with the injectable form, it takes 90 days to reach an effective dose, and GI adverse effects are frequent. Having an all-natural alternative that increases the body’s own GLP-1 and other satiety hormones provides additional choices for needle-phobic patients and those who cannot tolerate the side effects of GLP-1 RAs.

Figure 1: OASIS-4 Categorical Body Weight Reductions5

Buy Calocurb®

Looking for a natural way to support appetite control and satiety hormones? Calocurb® is an oral nutraceutical designed to stimulate the body’s own GLP-1, CCK and PYY release.

Buy Calocurb® Now

References

  1. Roy S. Novo’s Wegovy pill hits over 18,000 US prescriptions in strong debut week. Reuters. January 23, 2026. Accessed January 24, 2026. https://www.reuters.com/business/healthcare-pharmaceuticals/novos-wegovy-pill-tracks-18410-prescriptions-first-full-week-since-launch-2026-01-23/
  2. Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. NEJM. 2025;393(11):1077-1087. doi:https://doi.org/10.1056/nejmoa2500969
  3. Wilding JPH, Batterham RL, Calanna S. Once-weekly semaglutide in adults with overweight or obesity. NEJM. 2021;384(11):989-1002. doi:https://doi.org/10.1056/NEJMoa2032183
  4. Knop FK, Aroda VR, Ruben, et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023;402(10403). doi:https://doi.org/10.1016/s0140-6736(23)01185-6
  5. Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. Novonordisk.com. September 17, 2025. Accessed January 24, 2026. https://sciencehub.novonordisk.com/scientific-publications/articles/original-article.NN1995703685d.oral-semaglutide-at-a-dose-of-25-mg-in-adults.html
  6. Miller, M. Injectable → Oral Wegovy: How SNAC makes it possible. Linkedin.com. January 9, 2026. Accessed January 23, 2026. https://www.linkedin.com/pulse/injectable-oral-wegovy-how-snac-makes-possible-verma-miller-ph-d--rymce/
  7. Novo Nordisk Inc. Your compete guide to Wegovy® Pill. Wegovy.com. January 2026. Accessed January 24, 2026. https://www.wegovy.com/obesity/starting-wegovy/starting-wegovy-pill.html
  8. Ryan E. Transformative arrival of oral weight loss medicines in the US. Pharmaceutical Technology. January 19, 2026. Accessed January 25, 2026. https://www.pharmaceutical-technology.com/analyst-comment/transformative-arrival-of-oral-weight-loss-medicines-in-us/?cf-view
  9. Walker EG, Lo KR, Pahl MC, et al. An extract of hops (Humulus lupulus L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. Am J Clin Nutr. 2022;115(3):925-940. doi:10.1093/ajcn/nqab418
  10. Walker E, Lo K, Tham S, et al. New Zealand bitter hops extract reduces hunger during a 24 h water only fast. Nutrients. 2019;11(11):2754. doi:https://doi.org/10.3390/nu11112754
  11. Walker E, Lo K, Gopal P. Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting. Obes Pillars. 2024;11:100117. Published 2024 Jun 20. doi:10.1016/j.obpill.2024.100117
  12. Kim SH, Abbasi F, Nachmanoff C, et al. Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: a randomized controlled trial. Diabetes Obes Metab. 2021;23(2):489-498. doi:10.1111/dom.14242